Changes in Human Fecal Microbiota Due to Chemotherapy Analyzed by TaqMan-PCR, 454 Sequencing and PCR-DGGE Fingerprinting

Jutta Zwielehner1, Cornelia Lassl1, Berit Hippe1, Angelika Pointner1, Olivier J. Switzeny1, Marlene Remely1, Elvira Kitzweger2, Reinhard Ruckser2, Alexander G. Haslberger1*

1 Department of Nutritional Sciences, Vienna, Austria, 2 Sozialmedizinisches Zentrum Ost, Vienna, Austria

Abstract

Background: We investigated whether chemotherapy with the presence or absence of antibiotics against different kinds of cancer changed the gastrointestinal microbiota.

Methodology/Principal Findings: Feces of 17 ambulant patients receiving chemotherapy with or without concomitant antibiotics were analyzed before and after the chemotherapy cycle at four time points in comparison to 17 gender-, age- and lifestyle-matched healthy controls. We targeted 16S rRNA genes of all bacteria, Bacteroides, bifidobacteria, Clostridium cluster IV and XIVa as well as C. difficile with TaqMan qPCR, denaturing gradient gel electrophoresis (DGGE) fingerprinting and high-throughput sequencing. After a significant drop in the abundance of microbiota (p = 0.037) following a single treatment the microbiota recovered within a few days. The chemotherapeutical treatment marginally affected the Bacteroides while the Clostridium cluster IV and XIVa were significantly more sensitive to chemotherapy and antibiotic treatment. DGGE fingerprinting showed decreased diversity of Clostridium cluster IV and XIVa in response to chemotherapy with cluster IV diversity being particularly affected by antibiotics. The occurrence of C. difficile in three out of seventeen subjects was accompanied by a decrease in the genera Bifidobacterium, Lactobacillus, Veillonella and Faecalibacterium prausnitzii. Enterococcus faecium increased following chemotherapy.

Conclusions/Significance: Despite high individual variations, these results suggest that the observed changes in the human gut microbiota may favor colonization with C. difficile and Enterococcus faecium. Perturbed microbiota may be a target for specific mitigation with safe pre- and probiotics.

Introduction

The human intestinal ecosystem can be pictured as a microbial organ within a host organism involving a dynamic interplay between food, host cells and microbes [1]. The microbiota plays several significant roles in the digestion of food, energy regulation, generation of short-chain fatty acids, vitamin synthesis, prevention of colonization by pathogens and protection against cell injury [2,3,4]. Moreover, the gut microbiota influences the host by directing intestinal epithelial cell proliferation and differentiation, pH, and the development of the immune system [1]. Recent culture-independent molecular studies on healthy individuals have shown that the intestinal microbiota is specific to the host [5] and resilient to modifications over time, as it is able to form an alternative stable state after disruption [6,7]. A healthy microbiota contains a balanced composition of many classes of bacteria [8]. The fecal microbiota is dominated by three groups of anaerobic bacteria: the Clostridium cocoides group - clostridial cluster XIVa (reclassified as Blautia cocoides) [9], the Clostridium leptum group - Clostridium cluster IV, and the Bacteroides [10,11]. All three groups are known to positively affect the gut health through nutrient absorption, production of short chain fatty acids (SCFAs) and epithelial cell maturation [12,13]. Moreover, the subgroup bifidobacteria seems to be an important part of the gastrointestinal tract (GI) microbiota, being involved in the prevention of atopic disease, obesity and insulin resistance via enhanced barrier function of the gut epithelium [14].

To prevent the invasion of endogenous bacteria from oral cavity and the GI tract into the blood stream, three defense mechanisms are considered to be relevant: innate immunity, mechanical mucosal barrier, and colonization resistance [15]. However, chemotherapy damages the rapidly generated mucosal cells of the GI and the use of antibiotics disrupts the ecological balance, allowing pathogens such as Clostridium difficile to grow [16,17]. This bacterium is thought to be the causative agent in up to 20% of antibiotic-associated diarrhea (AAD) cases [18]. It is evident that the intestinal microbial ecosystem has an important but incompletely defined role in mucosal protection [19].
Macrositis is a major oncological problem, caused by the cytotoxic effects of cancer chemotherapy and radiotherapy [20]. Approximately 40% of patients receiving standard dose chemotherapy and up to 100% of patients receiving high dose chemotherapy and stem cell or bone marrow transplantation suffer from abdominal pain, ulceration, bloating and vomiting [21,22]. Although gastrointestinal disturbances (mucositis, diarrhea and constipation) and immunosuppression are well recognized side-effects of cancer treatment, very little research has been conducted into the underlying mechanisms and the changes in the composition of the microbiota. Because of these changes, nutrient absorption and other intestinal functions involving the microbiota may also be altered [23].

For this reason, we investigated shifts in fecal microbiota of patients receiving cancer chemotherapy with or without antibiotics in comparison to healthy control individuals. Prescription of antibiotics may become necessary in some individuals due to bacterial infection [24]. Samples were taken at four time points before and after chemotherapy to study changes in fecal microbiota over the course of time. In this study, we aimed to clarify how chemotherapy agents influence total fecal bacteria, Bacteroides, bifidobacteria, Clostridium cluster IV, Clostridium cluster XIVa and C. difficile using culture-independent methods assessing abundance and diversity. Four samples were also analyzed with 454 high-throughput sequencing.

Results

PCR-DGGE fingerprinting analysis shows decreased diversity of Clostridium clusters IV and XIVa in response to medical treatment compared to healthy individuals

DGGE fingerprinting analyses of all bacteria, Clostridium cluster IV and Clostridium cluster XIVa indicate a highly diverse dataset between individuals and uniqueness of fecal microbiota. Table 1 shows the average number of bands in cancer patients at the three time points and for controls over all time points. It becomes apparent that the average number of bands within Clostridium cluster IV declined immediately after chemotherapy (T1), followed by a recovery at T2. The average number of Clostridium cluster XIVa bands decreased after onset of chemotherapy and remained low also at T2. The datasets were subjected to principal component analysis (PCA). PCA extracts underlying components of samples according to their variance. Figure 1A illustrates the bacterial fingerprints of sample P01 over time. Figure 1B displays the PCA analysis of all bacteria. Most samples taken after chemotherapy are grouped together with all other samples. Patients who receive antibiotics are indicated as black symbols. They cluster together with the samples taken after chemotherapy and also with the majority of samples before chemotherapy and healthy controls. There are two exceptions though: Two samples from P07 after chemotherapy under antibiotic treatment are outliers in the lower right part of the PCA plot. P07 received blood stem cell transplantation resulting in a sharp decline in bacterial abundances as measured with quantitative PCR. The first two principal components explain 17.4% of variance.

Figure 1C shows the principal components analysis of Clostridium cluster IV. DGGE fingerprints of individuals after chemotherapy are found to be less variable than healthy controls and patients before onset of treatment. Although overlapping, PCA resulted in grouping of band patterns before and after chemotherapy. Additional effects by antibiotic treatment became evident: Antibiotic treatment significantly reduced the diversity within the Clostridium cluster IV ($p = 0.00003$, with Shannon diversity index being $1.4 \pm 0.7$ compared to patients under chemotherapy alone $2.1 \pm 0.6$). In the PCA plot, samples affected by antibiotics are found in the lower right corner of the plot. This means that they are grouped according to their variance along principal component (PC) 1 and 2. These two PCs explain 17.9% and 9.15% of the variance in the dataset, underlining the validity of this interpretation. Principal components analysis of Clostridium cluster XIVa is not shown.

Chemotherapeutic treatment with or without antibiotics decreases absolute bacterial numbers in comparison to healthy controls

To study whether chemotherapy with or without antibiotics changes the human GI microbiota composition in contrast to healthy individuals and over time, we investigated absolute numbers and relative percentages of bacterial subgroups. Absolute numbers give an indication about the direct antimicrobial effects of the treatments. Relative quantification is able to identify which bacterial subgroups are particularly affected and helps to describe the community disruption induced by chemotherapy with or without antibiotics. In absolute numbers, oncology patients harbored significantly less bacteria ($p < 0.05$) than healthy control (figure 2). From already low bacterial counts before chemotherapy, bacterial abundance significantly declined further ($p = 0.037$) immediately after chemotherapy (T1) and recovered 5–9 days later (T2) in comparison to time points before treatment (T0). Absolute numbers of bacteria in different time points of healthy controls are following a lognormal distribution in contrast to microbiota abundances in oncology patients. The decrease in total bacteria following chemotherapy ($p = 0.037$) was significantly greater than any variation in copy numbers observed in healthy controls ($p = 0.027$).

The observed decrease after chemotherapy affected the Bacteroides ($p = 0.044$), the bifidobacteria ($p = 0.034$) and Clostridium cluster IV ($p = 0.049$) as shown in figure 3. There were also fewer absolute numbers of Clostridium cluster XIVa, but this difference was not significant. All patients with fever showed an increase in total fecal microbiota (see figure 3). In sample P07 a sharp decline affecting all bacteria and bacterial subgroups was observed at T1 (figure 3), following blood stem cell transplantation and medical intervention.

Patients who received antibiotics had highest abundances of all bacteria ($p = 0.000003$) amongst all patients (data not shown). This bacterial overgrowth affected the Bacteroides, the bifidobacteria and Clostridium clusters IV and XIVa, since relative abundances of those subgroups did not stand out significantly. Thus, patients were grouped according to their chemotherapeutic cycle regardless whether or not they received antibiotics. The influence of antibiotics on the species composition as assessed with PCR-DGGE fingerprinting is discussed in the previous section.

Clostridium cluster XIVa shows great alterations due to chemotherapeutical interventions, while the Bacteroides and bifidobacteria seem to be marginally affected

Relative quantification of Clostridium cluster XIVa as percentage of total bacterial DNA showed that oncology patients harbored significantly less Clostridium cluster XIVa ($p = 0.047$) than healthy controls. The mean proportion of Bacteroides in stool samples was $26 \pm 12\%$ in chemotherapy patients and $22 \pm 14\%$ in healthy individuals. The mean percentage of bifidobacteria in patients was $0.8 \pm 1.4\%$ and $0.3 \pm 0.6\%$ in controls. Patients harbored on average $16 \pm 9\%$ of Clostridium cluster IV and $10 \pm 12\%$ of Clostridium cluster XIVa, while controls harbored $20 \pm 12\%$ and $24 \pm 15\%$ of clostridial clusters IV and XIVa.

Clostridium cluster XIVa higher before chemotherapy than after

The mean percentage of Clostridium cluster XIVa before chemotherapy was $22 \pm 13\%$ compared to after chemotherapeutic
cycles with 19±12%. The average amount of Bacteroides, bifidobacteria and Clostridium cluster IV were 26±6%, 1.4±2% and 16±9% at time points before chemotherapy and 28±14%, 0.5±1.2% and 18±12% after chemotherapy. Figure 3 illustrates the development of the microbiota in the course of antibiotic treatment. Data were normalized for clarity, so that changes in abundances from time point T0 (before onset of treatment) to T1 (1–4 days after chemotherapy) and T2 5–9 days after chemotherapy) rather than relative abundances are shown. It can be seen that chemotherapy causes a dramatic reduction of microbiota abundance immediately after chemotherapy, affecting all subgroups. As mentioned above, the significant decrease in all bacteria following chemotherapy was significantly greater than any variation in copy numbers observed in healthy controls (p = 0.027).

C. difficile colonization found in individuals receiving chemotherapeutic and antibiotic treatment

To find out whether the chemotherapeutic and antibiotic disruption favors the growth of pathogens, we investigated the abundance of C. difficile. Three out of seventeen patients receiving chemotherapy harbored C. difficile (data not shown). Patient P09 harbored C. difficile at all time points investigated. Mean proportion over all four samples of P09 was recorded as 0.4±0.7%, yet the highest level (1.22% of total bacteria) occurred at sampling point T1 immediately after chemotherapeutic and antibiotic intervention. C. difficile was detected in P11 (3.90% of all analyzed bacteria) after chemotherapeutic intervention at time point T1. P14 carried C. difficile in low abundance directly after onset of chemotherapy (0.003% of all analyzed bacteria). Samples of patients P09 and P11 at T0 and T1 were further analyzed in 454 sequencing.

Figure 1. A PCR-DGGE fingerprinting of 16S rRNA coding regions of dominant bacteria over time. Bands that become stronger or nearly disappear following a single chemotherapeutic treatment are indicated with arrows. B Principal components analysis (PCA) based on dominant bacteria PCR-DGGE fingerprinting. The two outliers in the lower right corner of the plot are two samples of P07 following blood stem cell transplantation. C PCA illustrating the development of Clostridium cluster IV diversity in the course of chemotherapy and antibiotic treatment. Cluster IV diversity drops right after chemotherapy, causing a grouping of samples. Samples under antibiotic treatment (indicated as grey dots) group even closer, indicating a strong influence of antibiotics on Clostridium cluster IV diversity. A, sample of P01 before chemotherapy B, C and D, samples of P01 after chemotherapy; E, healthy control; SL, unrelated standard lane; black symbols... patients under chemotherapy and antibiotic treatment.

doi:10.1371/journal.pone.0028654.g001

doi:10.1371/journal.pone.0028654.t001

| Time point | All bacteria | Clostridium cluster IV | Clostridium cluster XIVa |
|------------|--------------|------------------------|--------------------------|
| T0         | 18.9±4.6     | 14±7.0                 | 8±3.2                    |
| T1         | 19.7±4.9     | 10±6.0                 | 4.9±3.6                  |
| T2         | 19.6±3.6     | 15±6.0                 | 5.2±2.6                  |
| control    | 19.2±3.5     | 12.0±5.0               | 8.9±3.0                  |

Table 1. Number of bands observed in PCR-DGGE fingerprinting in oncology patients before chemotherapy (T0), immediately after chemotherapy (T1) and 5–9 days after chemotherapy (T2) and healthy controls averaged over all time points.
High throughput sequencing

High throughput sequencing showed a dramatic increase in sequences within the *Peptostreptococcaceae* towards sequences 98.9–100% similar to *C. difficile* (figure 4): *Clostridium bartletti* related sequences (98.1–100% similarity) were only detected before chemotherapy (T0). After chemotherapy (T1), 63 sequences 98.9–100% similar to *C. difficile* appeared in samples P11 and P09. In accordance with the phylogenetic classification by the ribosomal database project, they are shown as ‘unclassified *Peptostreptococcaceae*’ in figure 5.

Furthermore pronounced reductions of *Faecalibacterium* spp. as well as lactobacilli, *Veillonella* spp., bifidobacteria (in P09) and *E.coli*/*Shigella* became apparent in response to chemotherapy (figure 5). The abundance of lactobacilli decreased in both patients after chemotherapy, in P09 from already low levels. Individual P11 did not receive concomitant antibiotics, whereas P09 did. In P09 and P11 *Faecalibacterium* spp. decreased dramatically from 9.5% and 8.3% to 0.07% and 0.00%, respectively. In both individuals *Enterococcus faecium* increased following chemotherapy. Furthermore, less abundant sequences appeared that were attributable to bacterial genera not detected before chemotherapy. These genera are: *Eggerthella*, *Megasphaera*, *Parvimonas* (only in P11), *Anaerostipes*, *Eubacterium*, *Anaerococcus*, *Methylobacterium*, *Holdemania*, *Turicibacter*, *Akkermansia*, *Sutterella* (only in P09), *Sphingomonas*, *Anaerotruncus*, *Coprooccus*, *Streptococcus* and *Dorea*. Species with abundance <0.01% of all sequences are not shown in figure 5. The number of *Blautia* species from *Clostridium* cluster XIVa remained constant in the 454 sequencing datasets before and after chemotherapy.

**Discussion**

Chemotherapeutic and antibiotic use is associated with severe side effects such as mucositis, diarrhea and constipation. These side effects increase the cost of health services and are often life threatening [22]. Chemotherapeutic and antibiotic treatment has a detrimental impact on the host microbial ecosystem, which is important for host mucosal protection [19] and thereby increases the risk of infection [17]. Overgrowth of species with potential pathogenicity such as toxigenic *C. difficile* and inflammatory complications are among the most common serious complications of chemotherapy and antibiotic treatment among patients with cancer [15,17].

We investigated how the use of cancer chemotherapy (in some individuals together with antibiotic treatment) perturbs the fecal microbial ecosystem during the course of therapy. We assessed if the microbiota is able to return to its original profile after chemotherapeutic and antibiotic intervention with special interest in the abundance of *C. difficile*. We used a combination of molecular methods including high-throughput sequencing to compare diversity (PCR-DGGE) and abundance (qPCR) of all bacteria.
bacteria, Bacteroides, bifidobacteria, Clostridium cluster IV, Clostridium cluster XIVa and C. difficile between groups and different time points of chemotherapy. The majority of previous studies on the effect of chemotherapy on human fecal microbiota used standard microbiological culture techniques [16,22]. Other studies have focused on the colonization of pathogenic bacteria [17,25] in patients with cancer and chemotherapy-induced diarrhea [22,26]. As mentioned above, we used feces as source of information. Fecal microbial communities are composed of autochthonous gut members and transient bacteria. Even though the fecal microbiota might be different from the adherent microbiota, we chose fecal samples to investigate the microbial composition of the intestinal microbiota because they are easy to collect, are less invasive and reflect shifts in microbial population composition [11].

In this study, we assessed species richness using PCR-DGGE fingerprinting. Each lane of a PCR-DGGE gel represented a microbial fingerprint of a fecal sample; each band within a lane corresponded to one bacterial species, although different species may sometimes be represented by the same band [17]. It has also been observed that one bacterial strain may form several bands due to multiple 16S rRNA operons, e.g., E. coli (figure 4A). The limitations of DGGE in microbial analysis have been previously described [27]. Nevertheless, substantial information about species composition can be obtained from very complex microbial communities such as the gut microbiota [27]. We found decreased species richness immediately after the chemotherapeutic shot, especially within Clostridium cluster IV where the number of different bands decreased from 14±7 before chemotherapy (T0) to 10±6 bands shortly after (T1). The microbiota recovered to a richness of 15±6 Clostridium cluster IV bands per individual, but at a different composition, as evidenced by the grouping of samples in principal components analysis.

For quantification of fecal microbiota we used the strains Bacteroides thetaiotaomicronT, Bifidobacterium longum ssp. longumT and C. difficile as well as the clones CL16 and CC34 as standards. However, a mixture of different strains for qPCR standards might result in a more accurate image of the human microbiota. Therefore absolute amounts should be considered as semi-quantitative.

Grouping oncology patients with and without antibiotic treatment poses a risk to falsely interpret the effects of antibiotic treatment as effects of chemotherapy. Patients who received antibiotics had significantly higher bacterial abundances than patients without antibiotics. This observation might be the reason...
or without antibiotics. This indicates that the use of antibiotics does not fully explain the observed changes. Previous work [17] has also found additional effects of chemotherapy in cases under prophylactic antibiotic treatment. Although the Clostridium cluster IV abundance did not differ significantly due to antibiotics, PCR-DGGE fingerprints showed grouping of patients under antibiotic treatment in principal components analysis.

Despite high individual variations, we show a significantly lower absolute bacterial load in feces of patients receiving chemotherapy in comparison to healthy controls. These findings are in line with data from van Vliet et al. (2009) who reported 100-fold lower total bacterial numbers during chemotherapy than in healthy controls.

The abundance of fecal microbiota decreased after a single cycle of chemotherapy. After the end of chemotherapeutic administration the bacterial abundance recovered within a few days, sometimes even showing a “rebound-effect” with numbers elevating above initial levels. Relative numbers of Clostridium cluster IV and XIVa showed great alterations due to chemotherapeutic interventions, while the bifidobacteria seemed to be less affected. In agreement with previous results [16] increased counts of Bacteroides spp. were found in patients undergoing chemotherapy. Nyhölen et al. (2007) also reported significant increases in yeast in patients, making it a focus for further research in immunocompromised patients. Samples taken immediately after chemotherapy had a lower diversity within Clostridium cluster IV. Antibiotics strongly contributed to the reduced diversity of cluster IV but were not alone responsible for this effect. A few days later we observed a quantitative recovery, but not a recovery of the composition as evidenced by clustering of DGGE fingerprints.

The incidence of C. difficile in subjects P09 and P11 immediately after chemotherapy is accompanied by a decrease of the genera Bifidobacterium, Lactobacillus and Clostridium cluster IV. Sequences attributable to Faecalibacterium prausnitzii decreased dramatically from 9% to zero. The anti-inflammatory F. prausnitzii was associated with dietary fiber in colonic fermentation of healthy subjects [28] and found at low abundance in individuals suffering from inflammatory bowel diseases [29] [30,31]. Enterococcus faecium increased following chemotherapy, possibly filling the ecological niches vacated by the lactobacilli and bifidobacteria. Enterococcus faecium is a facultative pathogenic bacterium causing life-threatening infections especially in nosocomial settings [32]. Enterococcus faecium has previously been found to increase in wastewater upon treatment [33]. The acquisition of multi-resistant E. faecium strains has been described in hospital environments under high selective antibiotic pressure. Under such conditions probiotic strains were demonstrated as unable to prevent nosocomial infection [34].

Despite high individual variations, we show a significantly lower absolute bacterial load in feces of patients receiving chemotherapy in comparison to healthy controls. These findings are in line with data from van Vliet et al. (2009) who reported 100-fold lower total bacterial numbers during chemotherapy than in healthy controls.

The abundance of fecal microbiota decreased after a single cycle of chemotherapy. After the end of chemotherapeutic administration the bacterial abundance recovered within a few days, sometimes even showing a “rebound-effect” with numbers elevating above initial levels. Relative numbers of Clostridium cluster IV and XIVa showed great alterations due to chemotherapeutic interventions, while the bifidobacteria seemed to be less affected. In agreement with previous results [16] increased counts of Bacteroides spp. were found in patients undergoing chemotherapy. Nyhölen et al. (2007) also reported significant increases in yeast in patients, making it a focus for further research in immunocompromised patients. Samples taken immediately after chemotherapy had a lower diversity within Clostridium cluster IV. Antibiotics strongly contributed to the reduced diversity of cluster IV but were not alone responsible for this effect. A few days later we observed a quantitative recovery, but not a recovery of the composition as evidenced by clustering of DGGE fingerprints.

The incidence of C. difficile in subjects P09 and P11 immediately after chemotherapy is accompanied by a decrease of the genera Bifidobacterium, Lactobacillus and Clostridium cluster IV. Sequences attributable to Faecalibacterium prausnitzii decreased dramatically from 9% to zero. The anti-inflammatory F. prausnitzii was associated with dietary fiber in colonic fermentation of healthy subjects [28] and found at low abundance in individuals suffering from inflammatory bowel diseases [29] [30,31]. Enterococcus faecium increased following chemotherapy, possibly filling the ecological niches vacated by the lactobacilli and bifidobacteria. Enterococcus faecium is a facultative pathogenic bacterium causing life-threatening infections especially in nosocomial settings [32]. Enterococcus faecium has previously been found to increase in wastewater upon treatment [33]. The acquisition of multi-resistant E. faecium strains has been described in hospital environments under high selective antibiotic pressure. Under such conditions probiotic strains were demonstrated as unable to prevent nosocomial infection [34].

After chemotherapy less abundant sequences appeared that were not detected before treatment. These genera are: Eggerthella, Megaplasma, Parvimonas, Anaerostipes, Eubacterium, Anaerococcus, Methylobacterium, Holophaga, Lactobacillus, Streptococcus, Enterococcus, Coprococcus and Dorea. Eggerthella lentis was described to convert dietary lignans to the bioactive enterolactone [35]. Megaplasma spp. have been described as propionate-producers that utilize lactate [36] comparable to Veillonella spp. that were no longer detected by 454 sequencing after chemotherapy. The butyrate-producing Anaerostipes caccae and Eubacterium hallii utilize lactate as well. They were suggested to compete for lactate with sulfate-reducing bacteria such as Desulfo bacter piger whose preferred co-substrate is lactate. High concentrations of sulfate are toxic for the gut epithelium and may contribute to bowel disease [37]. Microorganisms of the genus Methylobacterium are facultative methylotrophic, gram-negative rods that are ubiquitous in nature and rarely cause human disease, except in subjects with pre-existing immunosuppression. For

---

**Figure 5. Heatmap showing abundances within the 454 sequencing dataset on the genus level.** High throughput sequencing of samples P09 and P11 before (T0) and after therapy (T1) further helped to characterize the influence of a single chemotherapeutic cycle on the G-microbiota. P11 was treated with chemotherapy alone and P09 also received antibiotic treatment. doi:10.1371/journal.pone.0028654.g005

---

for antibiotic treatment rather than its effect [24]. The abundance of bacterial subgroups, also Clostridium cluster IV, changed together with total bacteria both in patients with and without antibiotics. The sharp reduction of bacteria immediately after chemotherapy equally affected patients with and without antibiotics. In PCR-DGGE analysis we found that the all bacteria and Clostridium cluster XIVa fingerprints did not differ significantly in patients with
instance, in 2010, a case of *M. fujisawaense* infection was described in a patient with relapsed acute leukemia undergoing unrelated allogeneic hematopoietic stem cell transplantation [30]. *Turicibacter* is a poorly known genus previously found in weaned piglets, known to be susceptible to chlorotetracycline [39]. In humans, *Turicibacter* spp. have been found in the ileal pelvic pouch of a former ulcerative colitis patient [40]. *Akkermansia muciniphila* is a common mucin-degrading bacterium of the human GI. Its prevalence has been described as 10^6 cells/g feces in adults, decreasing with age [41]. *Dorea* spp. are mucosa-associated bacteria of the human GI that are members of the *Clostridium cocoides* rRNA group of organisms [42,43].

Further research is needed to elucidate if there is a causal relationship between growth of *C. difficile* and decreased abundance of lactobacilli, bifidobacteria and *Clostridium cluster IV*, especially the anti-inflammatory *Faecalibacterium prausnitzii*. The increase of mucin-degrading bacteria might be a result of *C. difficile* and probably also *E. faecium* associated inflammation of the gut epithelium. Mucus hypersecretion is a common symptom of irritable bowel syndrome, ulcerative colitis and bacterial infections of the gut epithelium [44,45]. The lactate-utilizing microbiota shifted from *Veillonella* spp. to *Aerococcus*, *Eubacterium* and *Megasphaera* spp. This change may be interpreted as a beneficial adaptation, because lactate could otherwise be used as a co-substrate for sulfate-reduction. Sulfate-reducing bacteria, however, were not detected here.

The oncology patients assessed here suffered from a variety of malignancies and received different chemotherapy treatment regimes. Only two participants (P01 and P08) had never received any cancer therapy before, while all others had a history of chemotherapeutic treatment. Therefore, the observed changes are likely to be influenced by previous cycles of chemotherapy. For example, the significantly lower bacterial abundance in cancer patients before chemotherapy in comparison to control could be a consequence of previous treatments. The results presented here illustrate changes due to a single chemotherapeutic cycle, but cannot rule out, that these changes occurred as a consequence of several chemotherapeutic cycles over the course of several years. Six cancer patients also received antibiotics. These patients were characterized by significantly elevated abundances of bacteria. This finding confirms the diagnosis 'bacterial infection' for which antibiotic treatment was prescribed. *Clostridium cluster IV* PCR-DGGE profiles revealed a shift in species composition by chemotherapeutics, and even more so by antibiotics. Thus we conclude that antimicrobial treatment significantly reduces the species richness of the *Clostridium cluster IV*, with the anti-inflammatory *Faecalibacterium prausnitzii* being the most abundant representative. Van Vliet et al. (2009) tested the effect of chemotherapy *in vitro* and showed a direct bacteriostatic effect of chemotherapeutics on bacterial growth.

Further research is needed to show whether changes in bacterial colonization play a role in the development and maintenance of mucosal barrier function, infection and inflammation [17].

The use of prebiotics, probiotics and bacterial products, such as butyrate to prevent mucosal barrier injury and its complications could be a promising concept in restoring impaired functions or enhancing specific desirable functions of the microbiota. The use of pre- and probiotics to affect the composition and metabolic activity of the fecal microbiota in times of cancer chemotherapy and immunosuppression might be part of future research.

In conclusion, chemotherapy treatment causes changes in fecal microbiota, which coincide with the development of *C. difficile* infection in some patients. These changes in microbiota may have systemic effects and may contribute to the development of chemotherapy-induced mucositis, influencing important beneficial functions of the microbial ecosystem.

### Materials and Methods

#### Ethics statement

The Viennese Human Ethics committee (3., Thomas-Klestil-Platz 8/2) under the chair of Dr. Karin Spacsek, approved the proposal of the project “Analysis of microbiota in feces of patients with immunosuppression”. Votum: EK 07-153-VK, 2006. From all participants involved in the study written consent was obtained.

#### Study participants and study design

Seventeen subjects receiving ambulant chemotherapy with or without antimicrobial therapy (aged 59±13 y, BMI 27±6) from the Sozialmedizinisches Zentrum Ost (SMZ Ost) in Vienna and seventeen healthy individuals (aged 65±18 y, BMI 24±5) joined this study. Four fecal samples within two weeks were collected of each ambulant oncology patient in order to collect samples before and after a single immune-suppressive chemotherapy cycle. The four samples obtained from every patient were grouped into three groups: samples taken before the day of chemotherapy (T0), samples taken 1–4 days after chemotherapy (T1) and samples taken 5–9 days after chemotherapy (T2). Healthy individuals also donated four samples during two weeks. Gender ratio among healthy controls was 56% female, 44% male. Oncology patients were 47% female and 53% male. Three out of seventeen patients (P04, P08, P13) had never received any chemotherapy before, while the others had a history of chemotherapy. Anonymous medical records reported types of malignancies as well as chemotherapeutic and antimicrobial treatment as shown in table 2.

We interviewed all study participants assessing age, gender, body length, weight, health status (chronic and acute diseases), and lifestyle aspects such as alcohol consumption and physical activity. Dietary habits were assessed using a food frequency questionnaire. Exclusion criteria for healthy controls were (a) antimicrobial medication (b) chemotherapeutic treatment and (c) pre- and probiotics at least three months before sample collection. Approval for this study was obtained from the Viennese Human Ethics committee (3., Thomas-Klestil-Platz 8/2).

#### Stool sample processing

After collection, study participants immediately stored their samples at -18°C in their homes. Stool samples were still frozen when brought to the laboratory and then immediately stored at −70°C. A 200 mg aliquot of each sample was treated twice for 45 s in a bead-beater (Mini-Beadbeater-8). Thereafter DNA was extracted using the QIamp® DNA Stool Mini Kit (QIAGEN) following the manufacturer’s protocol. The DNA was stored at −20°C until analysis.

#### Type strains

We used type strains, known to be part of the human gastrointestinal microbiota and cloned sequences to design a DGGE standard lane marker. Type strains *Bacteroides thetaiotaomicron* DSM 20797T, *Enterococcus faecium* DSM 20477T, *Lactobacillus reuteri* ATCC 55730T, *Bifidobacterium longum* ssp. *longum* DSM 20097T, *Escherichia coli* IMBH 252/07 and clones CL16 and CC34 (see below) were used for creating a comparable standard lane marker for DGGE gels analyzing all bacteria. *E.coli* IMBH 242/07 gave 4 bands due to its multiple operons for the 16S rRNA gene.

#### Clone library

To create a standard lane marker for DGGE analysis and to identify members of the *Clostridium cluster IVa* we constructed clone libraries from two stool samples of healthy volunteers. For this purpose PCR products amplified with primers 195-F [46] and...
Croc-R [47] were inserted into a p-GEM Easy Vector (Promega) following the instructions of the manufacturer. Nucleotide sequences were corrected for primer and vector sequences in CodonCodeAligner (www.codoncode.com) and taxonomically identified using the online tools of the ribosomal database project (http://rdp.cme.msu.edu/). The clone library used for creating a standard lane marker for DGGE analysis of Clostridium cluster IV has previously been described [48]. Clones CL16 (Clostridium leptum 16) and CC34 (Clostridium cocoides 34) were also used as positive controls in Taqman qPCR.

**Polymerase chain reaction (PCR)**

PCR was carried out amplifying 16S rRNA gene sequences from bacteria in fecal samples, type strains and cloned sequences for DGGE analysis as well as for creation of the clone library using group- and kingdom- specific primers (table 3). The PCR reaction mixture consisted of ready-to-use mastermix (Promega) with 1.5 mM MgCl2, 500 nM of primers and 2 μl of template DNA. When amplifying fecal samples, bovine serum albumin (Fermentas) was added to a final concentration of 400 μg/ml. We used a Robocycler (Stratagene) for all amplifications.

PCR-DGGE-fingerprinting

DGGE was performed as previously described [49]. Primer pairs and annealing temperatures to analyze the diversity of (a) all bacteria, (b) Clostridium cluster IV and (c) Clostridium cluster XIVa are described in table 3. PCR products were separated by polyacrylamide gels with a denaturing gradient of 30–60% for predominant bacteria, 30–50% for Clostridium cluster IV and 35–50% for Clostridium cluster XIVa. Electrophoresis was performed for 9 h at 129 V at 60°C (predominant bacteria), 5 h at 200 V at 60°C (Clostridium cluster IV) and 7 h at 200 V at 60°C (Clostridium cluster XIVa). Standard lane markers were created for each DGGE analysis assay to ensure reliable gel-to-gel comparison. These standard lane markers (described above) were loaded in triplicate on each gel to adjust for gradient-variations between gels. We analyzed PCR-DGGE fingerprints using GelComparII (www.applied-maths.com). When generating the band comparison, a 1% tolerance was selected. Principal components analysis (PCA) was applied on quantitative band comparison datasets in ‘R’ (www.r-project.org) using the default settings. Shannon diversity index was calculated on quantitative band information as well with the default settings implemented in the ‘vegan’ package in ‘R’ (www.r-project.org). Shannon index is defined as H = -∑ pi ln pi, where pi is the proportional abundance of species i. In short, the higher the Shannon index is, the higher is the diversity. For interpretation of results, samples were grouped into three groups: samples taken before the day of chemotherapy (T0), samples taken 1–4 days after chemotherapy (T1) and samples taken 5–9 days after chemotherapy (T2).

**Quantitative TaqMan qPCR**

The abundance of bacteria and bacterial subgroups was measured by 16S rRNA gene-targeting TaqMan qPCR in a Rotorgene 3000 (Corbett Life Science). Primers, annealing temperatures and expected product sizes are shown in table 4. Each sample was analyzed in duplicate. Amplifications were carried out in a total volume of 10 μl consisting of 5 μl Taq-Man SensiMix DNA Kit (Quantace), 1 μl of each primer and TaqMan probe (concentrations see table 4) and 10 ng of bacterial

---

**Table 2. Relevant clinical data of study participants undergoing immunesuppressive chemotherapy.**

| name         | diagnosis          | chemotherapeutic treatment                   | antimicrobial treatment                          | other condition            |
|--------------|--------------------|-----------------------------------------------|-------------------------------------------------|----------------------------|
| P01 urothel carcinoma | gemcitabine, cisplatinum |                                               |                                                 |                            |
| P02 plasmocytoma, multiple myeloma | bortezomib, dexamethasone |                                               |                                                 |                            |
| P03 Non-Hodgkin lymphoma | bendamustine |                                               |                                                 |                            |
| P04 ovarian fibroma | taxol, carboplatin |                                               | levofoxacin                                      |                            |
| P05 multiple myeloma | bortezomib, doxorubicin, dexamethasone | cotrimoxazole                                  | osteoporosis                                     |                            |
| P06 mamma carcinoma | pegylated liposomal doxorubicin hydrochloride, gemcitabine |                                               |                                                 |                            |
| P07 Non-Hodgkin lymphoma | high dose radiation therapy and PBSCT | cotrimoxazole, piperacillin, tazobactam | fever at 2nd and 3rd sampling                    |                            |
| P08 monoytic leukemia | cytarabine, idarubicin | cotrimoxazole, piperacillin, tazobactam | fever at 2nd sampling                            |                            |
| P09 acute leukemia | high dose Ara-C, radiated erythrocyte concentrate | piperacillin, tazobactam | fever at 2nd sampling                            |                            |
| P10 Non-Hodgkin lymphoma | ifosaminid, etoposid, methotretax |                                               | levofoxacin                                      |                            |
| P11 Acute lymphoblastic leukemia | cytarabine, methotretax |                                               | adipositas, hypertension                         |                            |
| P12 small intestinal tumor | cetuximab |                                               |                                                 |                            |
| P13 rectal tumor | capecitabine, oxaliplatin |                                               |                                                 |                            |
| P14 thymus tumor | taxol, carboplatin, bevacizumab, radiation |                                               |                                                 |                            |
| P15 Acute lymphoblastic leukemia | cyclophosphamide, methotretax, doxorubicin, cytarabine, vincristine |                                               | diabetes II                                      |                            |
| P16 Acute lymphoblastic leukemia | cytarabine, mitoxantrone |                                               |                                                 |                            |
| P17 colon tumor | oxaliplatin, capecitabine, bevacizumab, irinotecan, monoclonal antibodies |                                               |                                                 |                            |

PBSCT... peripheral blood stem cell transplant.

doi:10.1371/journal.pone.0028654.t002
DNA Amplification programs included an initial denaturation at 95 °C for 10 min followed by 40 cycles consisting of denaturation at 95 °C for 30 s, annealing at 55 °C (all bacteria, Clostridium cluster IV), 56 °C (Clostridium cluster XIVa), 58 °C (C. difficile) or 60 °C (Bacteroides, bifidobacteria) for 30 s and extension at 72 °C for 50 s.

We used tenfold serial DNA dilutions of type strains Bacteroides thetaiotaomicron T, Bifidobacterium longum ssp. longum T and C. difficile as well as cloned sequences and one fecal sample to construct standard curves for comparison of PCR reaction efficiencies among different experiments.

We quantified DNA of Bacteroides thetaiotaomicron T, Bifidobacterium longum ssp. longum T and C. difficile, using the nanodrop method and calculated DNA copies/μl through mean G+C content of each strain. Clones CL16 and CC34 were amplified with the SP6 Promoter Primer (Promega, Cat. # Q5011) and the T7 Promoter Primer (Promega, Cat. # Q5021) and the PCR product quantified using a nanodrop machine. Knowing the sequences of these two PCR products and their flanking vector sequences we could quantify the copy numbers and use it as standards. Relative percentages of bacterial subgroups were calculated in relation to total rRNA gene copies amplified with primer pair BAC-338-F and BAC-805-R [50].

We reviewed sensitivity of PCR reactions with stepwise dilutions of standard curve DNA until we achieved sensitive detection levels of PCR. The specificity was confirmed using non-target DNA.

### High throughput sequencing

In total, four samples (P09-T0, P09-T1, P11-T0, P11-T1) were amplified with primer 525F (5'- TCAGCAGCCGCGGTAATAC -3') and 926R (5'-TCCGTCAATTCCTTTGAGTTT -3') using a high-fidelity DNA polymerase (Phusion H, Finnzymes, Thermo Fisher Scientific) and submitted to 454 barcode sequencing (AGOWA, Berlin, Germany), resulting in a total of 113 000 reads. The sequences were trimmed and aligned using the pyro Table 3.

### 16S rRNA gene primers used for PCR-DGGE fingerprinting.

| Target organism | Primer | Sequence (5'-3') | Ann. temp (°C) | Reference |
|-----------------|--------|-----------------|--------------|-----------|
| All bacteria    | 27f    | GC TCGAGAGAGTTTACCTGGCTCAG | 57 | [52 T., Blocker 1989] |
|                 | 985r   | GATTGCTAGCTGGCTT | 57 | [53] |
|                 | 341F-GC | CCT AGG GGA GGC AGC AG | 55 | [49] |
|                 | 518r   | ATT ACC GCG GCT GCT GG | 55 | [54] |
| Clostridium cluster IV | sg-Clept-F-GC | GCA CAA GCA GTG GAT G | 55 | |
|                 | sg-Clept-R3 | CTT CCT CCG TTT TGT CAA | [55] | |
| Clostridium cluster XIVa | Cocc-F-GC | AAATGACGGTACCTGACTAA | 55 | |
|                 | Cocc-R | CTTCGGGTTTCTCGCCGA | [55] | |
| GC-clamp | CGGCGGGGCGGCGCGGCCCGGGCGGGGGCGGGGGCACC | [49] | |

### Primers and probes used for TaqMan qPCR quantification of 16S rRNA genes.

| Target organism | Primer and probe | Sequence (5'-3') | Size (bp) | Conc. (nM) | Reference |
|-----------------|-----------------|-----------------|-----------|------------|-----------|
| Bifidobacterium spp. | Forward primer | GCG TGC TTA ACA CAT GCA AGT C | 125 | 300 | |
|                 | Reverse primer | CAC CCG TTT CCA CCA GGA GCT ATT | 300 | | |
|                 | Probe | (FAM)- TCA CGT ATT ACT CAC CGG TTC GCC -(BHQ-1) | 150 | [56] | |
| Bacteroides | AllBac296f | GAG AGG AAG GTC CCC CAC | 106 | 300 | |
|                 | AllBac412r | CGC TAC TTG GTT GCT TCA G | 300 | | |
|                 | AllBac375Bhqr | (FAM)-CCA TTG ACC AAT ATT CCT AAC TGC TGC CTG CT-(BHQ-1) | 100 | [53] | |
| All bacteria | BAC-338-F | ACT CCT ACG GGA GGC AG | 468 | 1000 | |
|                 | BAC-805-R | GAC TAC CAG GGT ATC TAA TCC | 1000 | | |
|                 | BAC-S16-P | (FAM)- TGC CAG CAG CCG CCG TAA TAC-(BHQ-1) | 200 | [50] | |
| Clostridium cluster IV | sg-Clept-F | GCA CAA GCA GTG GAT T | 239 | 400 | |
|                 | sg-Clept-R3 | CTT CCT CCG TTT TGT CAA | 400 | [47] | |
|                 | Clept-P ++ | (FAM)-AGG GCT GCT CTC GGT -(BHQ-1) | 200 | This study | |
| Clostridium cluster XIVa | 195F | GCA GTG GGG AAT ATT GCA | 500 | [46] | |
|                 | Cocc-R | CTT TGA GGT TCA TCC TTC CGA A | 500 | | |
|                 | CoccP | (6-FAM)-AAATGACGGTACCTGACTAA-(BHQ-1) | 150 | [47] | |
| Clostridium difficile | CdiffF | TTG AGC GAT TTA CTT CCG TAA AGA | 1000 | [56] | |
|                 | CdiffR | TGT ACT GGC TCA CCT TGT ATA TCC A | 151 | 1000 | |
|                 | CdiffP | (6-FAM)-CCA CGC GGT ACT CAC CGG TCC G-(BHQ-1) | 200 | | |

doi:10.1371/journal.pone.0028654.t003
pipeline of the ribosomal database project (http://rdp.cme.msu.edu/). Only sequences longer than 150 bp were retained, resulting in 3806 to 6011 sequences per sample with the average lengths of 366 to 369 bp. All analyses were performed using the online tools of the ribosomal database project pyro pipeline (http://rdp.cme.msu.edu/). Results of the phylogenetic classification are shown as a heatmap [51]. The Peptostreptococcaceae, harbouring also *C. difficile*, from all four datasets were analyzed in more detail using the online tools of the ribosomal database project. 100% similar sequences were grouped together and their abundances shown together with a phylogenetic tree.

Data analysis
Statistical evaluation of differences between groups (chemotherapy and control) and changes within the chemotherapy group (all time points before and after chemotherapy) was carried out using the OriginPro version 8 (OriginLab, Northampton, MA). For two group comparisons of independent ordinal and interval values we used the two-sample *t*-test and the nonparametric Mann-Whitney *U*-test. For the analysis of related data we used the paired sample *t*-test or the non-parametric Wilcoxon signed-rank test. *P* values <0.05 were considered statistically significant. To show the decline in abundance immediately after chemotherapy qPCR results were plotted in heatmaps [51]. Values were *z*-scored for presentation in this heatmap showing changes over time rather than absolute abundances.

References

1. Turroni F, Ribbera A, Foroni E, van Sinderen D, Ventura M (2008) Human gut microbiota and bifidobacteria: from composition to functionality. Antonie Van Leeuwenhoek 94: 55–59.
2. Vrieze A, Hellerman F, Zoetendal EG, de Vos WM, Hoekstra JB, et al. (2010) The environment within: how gut microbiota may influence metabolism and body composition. Diabetologia 53: 606–613.
3. Chung H, Kasper DL (2001) Microbiota-stimulated immune mechanisms to maintain gut homeostasis. Curr Opin Immunol 12: 455–460.
4. Backhed F, Ley RE, Sonnentag JL, Peterson DA, Gordon JI (2005) Host-bacterial mutualism in the human intestine. Science 307: 1915–1920.
5. Ley RE, Hamady M, Lozupone C, Turnbaugh PJ, Ramazzry RR, et al. (2008) Evolution of mammals and their gut microbes. Science 320: 1649–1651.
6. Dethlefsen L, Relman DA (2011) Incomplete recovery and individualized responses of the human distal gut microbiota to repeated antibiotic perturbation. Proc Natl Acad Sci U S A 108: 5144–5149.
7. De La Cochetiere MF, Durand T, Lepage P, Bourreille A, Galmiche JP, et al. (2004) Intra-individual diversity in microbial ecology. Antonie Van Leeuwenhoek 73: 127–141.
8. Liu C, Finegold SM, Song Y, Lawson PA (2008) Reclassification of *Clostridium cocoides*, *Ruminococcus hansenii*, *Ruminococcus hydrogenotrophicus*, *Ruminococcus locii*, *Ruminococcus productus* and *Ruminococcus schinkii* as *Blautia cocoides* gen. nov., comb. nov., *Blautia hansenii* comb. nov., *Blautia hydrogenotrophica* comb. nov., *Blautia luti* comb. nov., *Blautia producta* comb. nov., *Blautia schinkii* comb. nov. and description of *Blautia wexlerae* sp. nov., isolated from human faeces. Int J Syst Evol Microbiol 58: 1896–1902.
9. Maukonen J, Matto J, Suihko ML, Saarela M (2008) Intra-individual diversity and similarity of salivary and faecal microbiota. J Med Microbiol 57: 1560–1568.
10. Eckburg PB, Bik EM, Bernstein CN, Purdom E, Dethlefsen L, et al. (2005) Diversity of the human intestinal microbial flora. Science 308: 1635–1638.
11. Louis P, Scott KP, Duncan SH, Flint HJ (2009) Understanding the effects of diet on gastrointestinal metabolism in the large intestine. J Appl Microbiol 102: 1197–1208.
12. Schiffrin EJ, Blum S (2002) Interactions between the microbiota and the intestinal mucosa. Eur J Clin Nutr 56 Suppl 3: S60–S64.
13. Cani PD, Neyrinck AM, Fava F, Knauf C, Burcelin RG, et al. (2007) Selective increase of bifidobacteria in gut microbiota improve high-fat-diet-induced diabetes in mice through a mechanism associated with endotoxaemia. Diabetologia 50: 2374–2383.
14. Guarner F, Malagelada JR (2003) Gut flora in health and disease. Lancet 361: 512–519.
15. Nyblen A, Ljungberg B, Nilsson-Ehle I, Nord CE (2002) Impact of combinations of antineoplastic drugs on intestinal microbiota in 9 patients with leukemia. Scand J Infect Dis 34: 17–21.
16. van Vliet MJ, Tissing WJ, Dun CA, Messen NE, Kamps WA, et al. (2009) Chemotherapy-induced diarrhea in pediatric patients with acute myeloid leukemia receiving antimicrobial prophylaxis leads to a relative increase of colonization with potentially pathogenic bacteria in the gut. Clin Infect Dis 49: 262–270.
17. Konig CJ, Jonkers DM, Stobberingh EE, Mulder L, Rombouts FM, et al. (2008) The effect of a multiplespecies probiotic on the intestinal microbiota and bowel movements in healthy volunteers taking the antibiotic amoxicillin. Am J Gastroenterol 103: 178–189.
18. Crockwell A, Amir E, Teggatz P, Barman M, Salzman NH (2009) Prolonged impact of antibiotics on intestinal microbial ecology and susceptibility to enteric *Salmonella* infection. Infect Immun 77: 2741–2753.
19. Sonis ST (1998) Mucositis as a biological process: a new hypothesis for the development of chemotherapy-induced stomatitis. Oral Oncol 34: 39–45.
20. Stringer AM, Gibson RJ, Logan RM, Bowen JM, Yeoh AS, et al. (2009) Enterococcal-induced mucositis is associated with changes in intestinal mucins. Cancer Chemother Pharmacol 64: 123–129.
21. Stringer AM, Gibson RJ, Logan RM, Bowen JM, Yeoh AS, et al. (2007) Chemotherapy-induced diarrhoea is associated with changes in the luminal environment in the DA rat. Exp Biol Med (Maywood) 232: 96–106.
22. Gibson RJ, Keefe DM (2006) Cancer chemotherapy-induced diarrhoea and constipation: mechanisms of damage and prevention strategies. Support Care Cancer 14: 890–900.
23. Bergmans DC, Bonten MJ, Gaillard CA, van Tiel FH, van der Geest S, et al. (1997) Indications for antibiotic use in ICU patients: a one-year prospective surveillance. J Antimicrob Chemother 39: 527–535.
24. Schalk E, Bohr UR, Konig B, Scheinflug K, Mohren M (2001) *Clostridium difficile*-associated diarrhoea, a frequent complication in patients with acute myeloid leukemia. Am Hematol 89: 9–14.
25. Abd El-Atti S, Wasicek K, Mark S, Hegazi R (2009) Use of Probiotics in the Management of Chemotherapy-Induced Diarrhea: A Case Study. J Parenter Enteral Nutr 33(5): 569–573.
26. Muyzer G, Smalla K (1998) Application of denaturing gradient gel electrophoresis (DGGE) and temperature gradient gel electrophoresis (TGGE) in microbial ecology. Antonie Van Leeuwenhoek 73: 127–141.
27. Benois DF, van der Werf IS, Wellin GW, Judd PD, Taylor MA, et al. (2010) Association between *Fecalibacterium prausnitzii* and dietary fibre in colonic fermentation in healthy human subjects. Br J Nutr. pp 1–8.
28. Cacciari S, Jebba V, Conte MP, Schippa S (2009) The microbiota in inflammatory bowel disease in different age groups. Dig Dis Sci 27: 252–258.
29. Sokol H, Pigneur B, Waterlot L, Lahlouli O, Bermudez-Humaran LG, et al. (2008) *Fecalibacterium prausnitzii* is an anti-inflammatory commensal bacterium identified by gut microbiota analysis of Crohn disease patients. Proc Natl Acad Sci U S A 105: 16731–16736.
30. Willing B, Halfvarson J, Dickaved J, Rosenqist M, Jarrer G, et al. (2009) Twin studies reveal specific imbalances in the mucosa-associated microbiota of patients with ileal Crohn’s disease. Inflamm Bowel Dis 15: 653–660.

Dietary aspects
We assessed the patients’ dietary habits using a food frequency questionnaire. All study participants (patients and controls) were omnivores and showed similar consumption patterns of liquids, alcohol, fruits, vegetables, grains and milk products. Healthy controls stated more frequent consumption of fruits, whole grain products and alcohol several times a week compared to patients receiving chemotherapy.

Acknowledgments
We thank all the study participants at the SMZO for their cooperation. We thank Dr. Viviana Klose and Mag. Varity-Annt Stulln for their guidance on using the GelCompareII program for the analysis of DGGE fingerprinting. Furthermore we would like to thank Dr. Guadalupe Pinar and Dr. Katja Sterflinger for their input and Dr. Konrad Domig for cultivation of type strains.

Author Contributions
Conceived and designed the experiments; JZ RR AGH. Performed the experiments; JZ AP CL BH OJS. Analyzed the data; JZ CL BH AP OJS RR AGH. Contributed reagents/materials/analysis tools; EM RR. Wrote the paper; JZ AGH.

Chemotherapy Changes Fecal Microbiota
32. Grobner S, Fritz E, Schoch F, Schaller M, Berger AC, et al. (2010) Lysozyme activates Enterococcus faecium to induce necrotic cell death in macrophages. Cell Mol Life Sci 67(19): 3331–44.

33. Ferreira da Silva M, Tinto I, Verissimo A, Boaventura RA, Nunes OC, et al. (2006) Antibiotic resistance of enterococci and related bacteria in an urban wastewater treatment plant. FEMS Microbiol Ecol 55: 322–329.

34. de Regt MJ, Willems RJ, Hene RJ, Siersema PD, Verhaar HJ, et al. (2010) Effects of probiotics on acquisition and spread of multi-resistant Enterococci. Antimicrob Agents Chemother Jul 54(7): 2001–5.

35. Woting A, Clavel T, Lob G, Blaut M (2010) Bacterial transformation of dietary lignins in gnotobiotic rats. FEMS Microbiol Ecol Jun 72(3): 567–14.

36. Flythe MD, Aiken GE (2010) Effects of hops (Humulus lupulus L.) extract on volatile fatty acid production by rumen bacteria. J Appl Microbiol Oct 109(4): 1169–76.

37. Marquet P, Duncan SH, Chassard C, Bernalier-Donadille A, Flint HJ (2009) Lactate has the potential to promote hydrogen sulphide formation in the human colon. FEMS Microbiol Lett 299: 129–134.

38. Fanci R, Corti G, Bartoloni A, Tortoli E, Mariottini A, et al. (2010) Unusual Methylobacterium fujisawaense Infection in a Patient with Acute Leukaemia Undergoing Hematopoietic Stem Cell Transplantation: First Case Report. Case Report Med 2010: 313514.

39. Retteldal E, Vilain S, Lindblom S, Lehnert K, Scafield C, et al. (2009) Alteration of the ileal microbiota of weaning piglets by the growth-promoting antibiotic chlortetracycline. Appl Environ Microbiol 75: 5489–5495.

40. Falk A, Olson C, Ahrne S, Molin G, Adawi D, et al. (2007) Ileal pelvic pouch microbiota from two former ulcerative colitis patients, analysed by DNA-based methods, were unstable over time and showed the presence of enterococci. Gut 18: 229–231.

41. Collado MC, Derrien M, Isolauri E, de Vos WM, Salminen S (2007) Intestinal microbiota present in infants, adults, and the elderly. Appl Environ Microbiol 73: 7767–7770.

42. Tweddle MJ, Lait K, Handschur M, Lawd C, Lapin A, et al. (2009) Combined PCR-DGGE fingerprinting and quantitative-PCR indicates shifts in faecal population sizes and diversity of Bacteroides, bifidobacteria and Clostridium cluster IV in institutionalized elderly. Exp Gerontol 44: 440–446.

43. Nomura T, Ohkusa T, Okayasu I, Yoshida T, Sakamoto M, et al. (2005) Effects of Probiotics on Acquisition and Spread of Multi-resistant Enterococci. Report Med 2010: 313514.

44. Nomura T, Ohkusa T, Okayasu I, Yoshida T, Sakamoto M, et al. (2005) Antibiotic resistance of enterococci and related bacteria in an urban wastewater treatment plant. FEMS Microbiol Ecol 55: 322–329.

45. Guilmeau S, Flandeau M, Bancroft L, Sellers RS, Tear B, et al. (2008) Intestinal deletion of Poful1 in the mouse inactivates notch signaling and causes enterocolitis. Gastroenterology 135: 849–860, 860 e841–846.

46. Meier H, Amann R, Ludwig W, Schäfer KH (1999) Specific oligonucleotide probes for in situ detection of a major group of gram-positive bacteria with low DNA G+C content. Syst Appl Microbiol 22: 186–196.

47. Matsuki T, Watanabe K, Fujimoto J, Takada T, Tanaka R (2004) Use of 16S rRNA gene-targeted group-specific primers for real-time PCR analysis of predominant bacteria in human feces. Appl Environ Microbiol 70: 7220–7228.

48. Edwards U, Rogall T, Blocker H, Emde M, Bottger EC (1989) Isolation and direct complete nucleotide determination of entire genes. Characterization of a gene coding for 16S ribosomal RNA. Nucleic Acids Res 17: 7843–7853.

49. Yusuf H, Hartung K, Wieland G, Kramer I, Smalla K (1999) Polynucleotide probes that target a hypervariable region of 16S rRNA genes to identify bacterial populations by denaturing gradient gel electrophoresis analysis of polymerase chain reaction-amplified genes coding for 16S rRNA. Appl Environ Microbiol 59: 695–700.

50. Yu Y, Lee C, Kim J, Hwang S (2005) Group-specific primer and probe sets to detect methanogenic communities using quantitative real-time polymerase chain reaction. Biotechnol Bioeng 89: 670–679.

51. Symons S, Zillips C, Batelle F, Nieselt K (2010) Integrative systems biology visualization with MAYDAY. J Integr Bioinform Mar 25: 73.

52. Edwards U, Rogafl T, Blocker H, Emde M, Bottger EC (1989) Isolation and direct complete nucleotide determination of entire genes. Characterization of a gene coding for 16S ribosomal RNA. Nucleic Acids Res 17: 7843–7853.

53. Heuer H, Hartung K, Wieland G, Kramer I, Smalla K (1999) Polynucleotide probes that target a hypervariable region of 16S rRNA genes to identify bacterial isolates corresponding to bands of community fingerprints. Appl Environ Microbiol 65: 1045–1049.

54. Neeft JM, Van de Peer Y, De Rijk P, Goris A, De Wachter R (1991) Compilation of small ribosomal subunit RNA sequences. Nucleic Acids Res 19 Suppl: 2015–2015.

55. Shen J, Zhang B, Wei G, Pang X, Wei H, et al. (2006) Molecular profiling of the Clostridium leptum subgroup in human fecal microflora by PCR-denaturing gradient gel electrophoresis and clone library analysis. Appl Environ Microbiol 72: 5232–5238.

56. Penders J, Vink C, Driessen C, Londen N, Thijs C, et al. (2005) Quantification of Bifidobacterium spp., Escherichia coli and Clostridium difficile in faecal samples of breast-fed and formula-fed infants by real-time PCR. FEMS Microbiol Lett 243: 141–147.